Hospital Amaral Carvalho
Hospital Amaral Carvalho
R. Doná Silvéria, 150 - Chácara Braz Miraglia, Jaú - SP, 17210-080, Brazil
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Patricia Beato
Guilherme Costa
Weslley Aleixo
Edson Barreira
Debora Cristina de Campos Chicacci
Adriana Coutinho
Jonathan dos Santos
Alvaro Lança
Ederson Mattos
Brigida Ranzani
Natalia Rodrigues
Elaine Paris de Oliveira Rosa
Luana Dias Viera
Eloisa Negreiros D. Stivam
Márcia Higashi
Open studies
Non-Hodgkin Lymphoma
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma - EPCORE FL-1 - AbbVieSee more
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - EPCORE DLBCL-2 - AbbVieSee more
Bladder Cancer
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy - IMvigor011 - Hoffmann-La RocheSee more
Breast Cancer
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC - Gloria - OBI Pharma, IncSee more
Leukemia
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia - VenCM - Hospital Amaral Carvalho. Jau, SP, BrazilSee more
Lymphoma
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma - EPCORE FL-1 - AbbVieSee more
Multiple myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - Successor-1 - Bristol-Myers SquibbSee more
Myeloproliferative syndromes
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment - MYF3001 - Geron CorporationSee more
